Plant pests such as bacteria and fungi lead to significant yield losses in agriculture. In order to develop new strategies ...

Home > Press release: New insights into the immune response of ... A team headed by biologist Prof Jörg Kudla has identified important components and mechanisms of the molecular machinery that ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biotech company with a market capitalization of $631 ...

Guillain-Barré Syndrome (GBS) is a rare neurological disorder where the immune system attacks nerves. Learn about symptoms, ...

Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

SCIENCE: Trudeau Institute, Ampersand Biosciences producing tools for flu research with $1M grant SARANAC LAKE — Local research and biotechnology laboratories Trudeau Institute and Ampersand ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...